X Yang1, L Gao1, X Wu2, Y Zhang2, D Zang3. 1. Department of Neurology, Tianjin First Center Hospital of Tianjin Medical University, Tianjin, China. 2. Department of Neurology, Tianjin First Center Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China. 3. Department of Neurology, Tianjin First Center Hospital, Tianjin Medical University, Tianjin, China.
Abstract
OBJECTIVES: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with complicated pathogenesis. No effective diagnostic test and cure exists for the disease at present. We detected the levels of MIP-1α in cerebrospinal fluid (CSF) and serum and then further evaluated whether MIP-1α levels correlate with the severity and progression of ALS. METHODS: We used ELISAs to detect MIP-1α levels from 58 patients with ALS and 45 age- and gender-matched controls. The patients with ALS were also clinically evaluated with the revised ALS functional rating scale (ALSFRS-r). Moreover, we followed up with 40 cases of ALS by way of call or clinic visit 4 years after enrollment in this study. Finally, we assessed the correlations between MIP-1α levels and various clinical parameters. RESULTS: We found that the levels of MIP-1α in patients with ALS significantly increased compared to controls and they were positively correlated with duration. MIP-1α showed negative correlations with disease progression rate and the decrease in ALSFRS-r. Furthermore, the cumulative survival of patients with ALS with high levels of MIP-1α exceeded patients with low MIP-1α levels. CONCLUSIONS: MIP-1α levels increased in both CSF and serum of patients with ALS, and it may be a potential neuroprotective biomarker in ALS.
OBJECTIVES:Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with complicated pathogenesis. No effective diagnostic test and cure exists for the disease at present. We detected the levels of MIP-1α in cerebrospinal fluid (CSF) and serum and then further evaluated whether MIP-1α levels correlate with the severity and progression of ALS. METHODS: We used ELISAs to detect MIP-1α levels from 58 patients with ALS and 45 age- and gender-matched controls. The patients with ALS were also clinically evaluated with the revised ALS functional rating scale (ALSFRS-r). Moreover, we followed up with 40 cases of ALS by way of call or clinic visit 4 years after enrollment in this study. Finally, we assessed the correlations between MIP-1α levels and various clinical parameters. RESULTS: We found that the levels of MIP-1α in patients with ALS significantly increased compared to controls and they were positively correlated with duration. MIP-1α showed negative correlations with disease progression rate and the decrease in ALSFRS-r. Furthermore, the cumulative survival of patients with ALS with high levels of MIP-1α exceeded patients with low MIP-1α levels. CONCLUSIONS: MIP-1α levels increased in both CSF and serum of patients with ALS, and it may be a potential neuroprotective biomarker in ALS.
Authors: Laura Moreno-Martínez; Miriam de la Torre; Janne M Toivonen; Pilar Zaragoza; Alberto García-Redondo; Ana Cristina Calvo; Rosario Osta Journal: Front Immunol Date: 2019-04-12 Impact factor: 7.561
Authors: Shaochun Zhu; Anna Wuolikainen; Junfang Wu; Anders Öhman; Gunnar Wingsle; Thomas Moritz; Peter M Andersen; Lars Forsgren; Miles Trupp Journal: J Mol Neurosci Date: 2019-11-12 Impact factor: 3.444
Authors: Laura Moreno-Martinez; Miriam de la Torre; María J Muñoz; Pilar Zaragoza; José Aguilera; Ana C Calvo; Rosario Osta Journal: Toxins (Basel) Date: 2020-05-17 Impact factor: 4.546
Authors: Marie Dreger; Robert Steinbach; Markus Otto; Martin R Turner; Julian Grosskreutz Journal: J Neurol Neurosurg Psychiatry Date: 2022-02-01 Impact factor: 13.654